PolyPid Ltd.

Jul 01, 2020

PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

Jun 30, 2020

PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 26, 2020

PolyPid Ltd. Announces Pricing of Initial Public Offering

Feb 27, 2020

PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-cardiac Surgery

Feb 23, 2020

PolyPid Announces Intention to Submit Confidential Draft Registration Statement for Proposed U.S. Initial Public Offering

Sep 04, 2019

PolyPid Announces Completion of $50 Million Series E-1 Financing

Aug 12, 2019

PolyPid Completes Enrollment of Phase 2 Clinical Trial with D-PLEX100 in Abdominal Surgery

Nov 12, 2018

PolyPid Announces FDA Clearance of Investigational New Drug Application (IND) to Commence Pivotal Phase 3 Clinical Trial of D-PLEX[100] for the Prevention of Sternal Wound Infection Post-Cardiac Surgery

Oct 15, 2018

PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections

Dec 21, 2017

PolyPid Appoints Jacob Harel as Chairman of the Board of Directors